Fourth Glaxo AIDS drug gets backing of a U.S. Federal panel
A U.S. federal panel recommended approval of Glaxo Wellcome Inc.'s fourth AIDS drug, Ziagen, despite evidence of serious, and sometimes deadly, allergic reactions in about 3% of patients. The drug